anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recently, a lot of research has been done to test for certain markers like fluorescence in situ hybridization (FISH), digital image analysis (DIA), and quantifiable morphometric results in biliary stricture brushings. Recently, polysomy FISH has been studied as a promising marker in predicting cancer in a pancreato-biliary stricture. Many genetic, epigenetic, and protein alterations arise during pancreaticobiliary tumor process. The types of markers that have been commonly evaluated as diagnostic assays are mutations, chromosomal gains and losses, and DNA methylation alterations. However there are only a few studies in this area. Testing for these markers can help determine whether the narrowing or stricture in your bile duct is cancer or not.
Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.
NASCOBAL is a nasal spray available in a dosage strength of 500 mcg cyanocobalamin/0.1 mL (per actuation). It is supplied in boxes of 4 single-use nasal spray devices and a package insert (NDC 49884-270-82). 

Protect from light. Keep covered in carton until ready to use. Store upright at controlled room temperature 15°C to 30°C (59°F to 86°F). Protect from freezing.
Shenfu injection is a traditional Chinese medicine formulation containing ginseng (Panax; family: Araliaceae) and aconite (Radix aconiti lateralis preparata, Aconitum carmichaeli Debx; family: Ranunculaceae) with Ginsenosides and aconite alkaloids as the main active ingredients. Its quality is strictly controlled in compliance with the standard of the China Ministry of Public Health (official approval code: certification number Z20043117; No. 110804, Ya'an, China). Animal studies have shown that Shenfu injection has protective effects against reperfusion injury through multiple pharmacologic effects, including scavenging free radicals, inhibiting inflammatory mediators, suppressing cell apoptosis, and inhibiting calcium overload. However, few data are available regarding its efficacy in humans. We aimed to determine whether perioperative use of Shenfu injection, as compared to placebo, might reduce infarct size in patients with STEMI undergoing primary PCI.
No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
This is a multicenter, randomized (study drug is assigned by chance), double-blind (neither sponsor, physician nor patient knows the name of the assigned study drug), Phase III study to compare the efficacy, tolerability and safety of TMC435 (in development for treatment of chronic hepatitis C virus \[HCV\] infection) versus placebo (a preparation containing no drug used as control) as part of a treatment regimen including peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) (both current therapies for HCV) in adult treatment-naïve patients (patients who have never taken HCV medications) with genotype 1 Hepatitis C virus (HCV) infection. The study will consist of a screening period with a maximum duration of 6 weeks, a response guided 24- or 48-week (TMC435 treatment groups) or 48-week (control group) treatment period, and a post-therapy follow-up period up to 72 weeks after the start of treatment. Patients will be randomly assigned in a 1:1:1 fashion to receive TMC435 or placebo, stratified by HCV genotype 1 subtype and IL28B genotype within each country. In the first 24 weeks, patients will receive 12 weeks TMC435 100 or 150 mg or placebo once-daily (q.d.) plus PegIFNα-2a plus RBV, after which they will continue with PegIFNα-2a and RBV. Response-guided treatment criteria will be used to determine PegIFNα-2a and RBV total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. In the control group, all patients will be required to complete 48 weeks of treatment with PegIFNα-2a and RBV. In all 3 treatment groups, there will be a post-therapy follow-up period up to 72 weeks after the start of treatment. The total study duration for each patient will be a maximum of 78 weeks (including the 6-week screening period).
FIELD: medicine, gastroenterology. SUBSTANCE: method involves the use of detoxication and separated nutrition. Detoxication of organism is carried out by intake of 180-200 ml plant purge warm an aqueous infusion based on herb, bark or fruits taken at amount 1-16 g/200-250 ml water or tablets based on plant base which were intaken 10-20 min before supper for 1.5-2.5 months. The separated nutrition is carried out by successive intake of food liquid, fruits and/or crude vegetables no containing starch followed by intake of protein and then - carbohydrate food with fat addition. Body mass is controlled by fruit-vegetable diet, twice per a week, at simultaneous organism detoxication. Mixture of senna or purging buckthorn, or flax seeds and peppermint is used as a mixture of purgative herbs taken at ratio (2-3):1, respectively. Nettle, flax seeds, bur-marigold and peppermint taken at ratio = (2-3):(2-3):(2-3):1, respectively, were used preferably for pregnant women and nursing mothers but in this case senna leaves and purging buckthorn were not used. EFFECT: enhanced effectiveness of method. 3 cl
The invention provides application of sennoside A in preparing a medicine for treating liver cancer. The invention also provides application of the serine protease inhibitor superfamily protein 2 as a target for screening medicines for treating liver cancer. The invention also provides application of the WNT signal pathway inhibitor 1 as a target for screening drugs for treating liver cancer. The invention also provides application of the keratin KRT7 as a target for screening medicines for treating liver cancer. The invention also provides application of the keratin KRT81 as a target for screening medicines for treating liver cancer. The invention proves that sennoside A has the effect of treating liver cancer, and successfully screens and verifies the target point and related passages of sennoside SA for playing the role of resisting hepatocellular carcinoma metastasis.
In one aspect, methods of promoting asymmetric nerve growth and/or regeneration are described herein. In some embodiments, such a method comprises exposing a population of transected or severed nerves to a first molecular growth cue and to a second molecular growth cue. The population of transected nerves comprises one or more nerves of a first nerve type and one or more nerves of a second nerve type differing from the first nerve type. Additionally, the first molecular growth cue preferentially promotes growth of the first nerve type, as compared to the second nerve type. Similarly, the second molecular growth cue preferentially promotes growth of the second nerve type, as compared to the first nerve type. Moreover, the first molecular growth cue is spatially separated from the second molecular growth cue.
The nucleic acid gamete of affiliating human albumin features its DNA molecule in the nucleotide sequence of ATCCGCCTGATTAGCGATACTGGGACTGACTGATACGAAGGCATGATTG GGACACTACTTGAGCAAAATCACCTGCAGGG. It is prepared through a systemic evolution index enriching process for screening human albumin oligonucleotide gamete, and may be used for replacing antibody in detecting, separating and purifying human albumin. The derived RNA sequence has the same function as the oligonucleotide sequence derived through hybridization, deletion, increment, displacement or modification. The present invention has the features of simplicity, high speed, low cost, etc. The oligonucleotide has relatively small molecular weight and may be synthesized chemically in low cost. It has affinity and specificity higher than that of antibody, easy marking optionally in different parts, high repeatability and high stability.
Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and TGFb DNRII-transduced autologous TIL and NGFR-transduced autologous T lymphocytes IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
There is provided an apparatus for gene therapy to transfer or introduce, in vivo, a gene for treatment into a cell located at a target portion of a patient, so that the gene can be transferred with a high probability within a short period of time. The apparatus is applicable to all cell species. In addition to simple supply of a gene to the cell of the patient, the gene is forcibly transferred to the cell without depending on natural cellular physiology. For example, catheters are mounted on a probe inserted into a body cavity, and the gene is supplied from a reservoir which stores the gene to the surface of a human living cell of the target portion in the body cavity through needle cannulas attached to the distal ends of the catheters. A pulse voltage is applied to the needle cannulas to form a pore in the surface of the human living cell upon application of the pulse voltage. The gene is transferred into the human living cell through the pore.
Mercapto acyl-carnitines (I) [X-=halogen ion, R=C2-10 mercapto acyl! are prepd. for use as medicines for skin disease and respiratory organ disease. Carnitine hydrochloride is reacted with halogen acyl chloride in inert organic solvent at 30-60≰C to give halogen acyl carnitine. The halogen acyl carnitine is reacted with a compd. selected from alkali metal sulfide and acid sulfide at neutral pH, and held at room temp. to give the title compd..
The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
The Intervention is a text messaging algorithm that will operate like a chatbot, querying adolescents with T1D about their confidence with different aspects of T1D self-management as they are preparing to transition to adult diabetes care. The intervention has 4 components of messaging: personalized Educational Content, Standard Educational Curriculum, Provide participant compensation for filling out the questionnaires, Question \& Answer feature.
A cleaning composition and a method of manufacturing the same are disclosed. The cleaning composition includes a substantially water-base carrier, an abrasive material, a thickening material and an antiseptic material. The water-base carrier includes a structuring agent, a moisturizing agent and a preservative. The structuring agent is stearic acid, palmitic acid, polyethylene glycol or a combination thereof. The moisturizing agent is coffee berry extract, coconut oil, coconut water, apricot kernel oil, avocado oil, canola oil, cocoa butter, coco- caprylate/caprate, lemon oil, sunflower seed oil, vegetable oil, water and waxes or a combination thereof. The preservative is phenoxyethanol, potassium sorbate, polyquaternium- 1, benzalkonium halides, parabens, benzyl alcohol, chlorobutanol, phenol, sorbic acid, thimerosal or a combination thereof. The abrasive material is hemp protein, the thickening material is hemp seed oil and the antiseptic material is tea tree oil.
BACKGROUND: Aortic valve sclerosis (AVSc) presents similar pathogenetic mechanisms to coronary artery disease and is associated with short- and long-term mortality in patients with coronary artery disease. Evidence of AVSc-specific pathophysiological traits in acute myocardial infarction (AMI) is currently lacking. Thus, we aimed to identify a blood-based transcriptional signature that could differentiate AVSc from no-AVSc patients during AMI.
METHODS: Whole-blood transcriptome of AVSc (n=44) and no-AVSc (n=66) patients with AMI was assessed by RNA sequencing on hospital admission. Feature selection, differential expression, and enrichment analyses were performed to identify gene expression patterns discriminating AVSc from no-AVSc and infer functional associations. Multivariable Cox regression analysis was used to estimate the hazard ratios of cardiovascular events in AVSc versus no-AVSc patients.
RESULTS: This cross-sectional study identified a panel of 100 informative genes capable of distinguishing AVSc from no-AVSc patients with 94% accuracy. Further analysis revealed significant mean differences in 143 genes, of which 30 genes withstood correction for age and previous AMI or coronary interventions. Functional inference unveiled a significant association between AVSc and key biological processes, including acute inflammatory responses, type I IFN (interferon) response, platelet activation, and hemostasis. Notably, patients with AMI with AVSc exhibited a significantly higher incidence of adverse cardiovascular events during a 10-year follow-up period, with a full adjusted hazard ratio of 2.4 (95% CI, 1.3-4.5).
CONCLUSIONS: Our findings shed light on the molecular mechanisms underlying AVSc and provide potential prognostic insights for patients with AMI with AVSc. During AMI, patients with AVSc showed increased type I IFN (interferon) response and earlier adverse cardiovascular outcomes. Novel pharmacological therapies aiming at limiting type I IFN response during or immediately after AMI might improve poor cardiovascular outcomes of patients with AMI with AVSc.
This is a randomized, paralleled study. Patients will be divided into two groups of treatment and control. all of them will receive conventional treatment based on specific condition, including digitalis, milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), and antiplatelet aggregation etc. Treatment group patients will receive hUC-MSC. Follow-up visit will occur on 3 months, 6 months, and 12 months after the cell transfusion. Vital signs, blood routine test, urine routine test, liver function examination, etc, will be placed to evaluate the safety of hUC-MSC treatment. And the change of symptoms to evaluate the efficacy.
The present disclosure relates to systems, methods, and media for generating reports based on medical images of patients. An exemplary system includes a communication interface configured to receive a medical image acquired by an image acquisition device. The system also includes at least one processor. The at least one processor is configured to receive a user selection of at least one medical image in at least one view. The at least one processor is further configured to automatically generate keywords describing the selected medical image based on a learning network comprising a convolutional neural network and a recurrent neural network connected in series. The at least one processor is further configured to receive a keyword selection among the generated keywords and generate a report based on the keyword selection. The system additionally includes a display configured to display the selected medical image and the report.
The term "microbiome" refers to the collection of bacterial species that reside in the human body's tissues. Sometimes, it is used to refer to all microbial entities (bacteria, viruses, fungi, and others) which colonize the human body. It is now generally acknowledged that the microbiome plays a critical role in the host's physiological processes and general well-being. Changes in the structure and/or function of the microbiome (dysbiosis) are linked to the development of many diseases including cancer. The claim that because of their negatively charged membrane, cancer cells are more vulnerable to some bacteria than normal cells and that is how the link between these bacteria and cancer evolved has been refuted. Furthermore, the relationship between the microbiome and cancer is more evident in the emerging field of cancer immunotherapy. In this narrative review, we detailed the correlation between the presence/absence of specific bacterial species and the development, diagnosis, prognosis, and treatment of some types of cancer including colorectal, lung, breast, and prostate cancer. In addition, we discussed the mechanisms of microbiome-cancer interactions including genotoxin production, the role of free radicals, modification of signaling pathways in host cells, immune modulation, and modulation of drug metabolism by microbiome. Future directions and clinical application of microbiome in the early detection, prognosis, and treatment of cancer emphasizing on the role of fecal transplantation, probiotics, prebiotics, and microbiome biomarkers were also considered.
Generally described, the present disclosure relates to medical information and more particularly, to a system for migrating personal health information and methods thereof. In an illustrative embodiment, the migration platform can include an importation and reconciliation module, migration form and exportation module. The importation module can load the migration platform with known information from a source system. In turn, the reconciliation module can determine what elements can be automatically transferred to the target system and which elements to apply migration business rules to. A migration technician can convert elements which cannot be automatically migrated. The migration form can break down and group the patient's chart into sections and elements for review by the technician. The migration form can also display the elements in an easy-to-follow format and manage pairs of information. The exportation module of the migration platform can take the completed chart, after review, and populate the target system.
PURPOSE:To provide a hair cosmetic containing a chitosan polyoxyalkylene ether and an ultraviolet absorber at a specific ratio, imparting the hair with natural luster and effective for preventing the damage of the hair. CONSTITUTION:The objective cosmetic contains 0.01-10wt.% of a chitosan polyoxyalkylene ether produced by etherifying chitosan with one or more alkylene oxides (especially propylene oxide or a combination of ethylene oxide and propylene oxide) and 0.01-5wt.% of an ultraviolet absorber (e.g. ethyl p- aminobenzoate, the compound of formula I or formula II). The hair cosmetic is preferably used in a non-rinsing cosmetic form to be directly applied to the hair, e.g. hair-liquid, hair-cream, hair oil, hair get, hair mist, hair foam, set lotion, hair mousse and hair spray. It can be used by filling in a pressure vessel together with a propellant.
PURPOSE:To provide a water-containing skin cosmetic containing a hydrophilic fibroin-coated pigment produced by attaching a hydrophilic nonionic surfactant to a fibroin-coated pigment, and having excellent storage stability, redispersibility, adhesion to the skin and moisture-retainability. CONSTITUTION:A hydrophilic fibroin-coated pigment attached with 0.1-5wt% hydrophilic nonionic surfactant is produced by coating the surface of base pigment particles (e.g. talc, kaolin, titanium oxide, etc.) with the film of regenerated fibroin and the fibroin-coated pigment is immersed in a mixed solution of a hydrophilic nonionic surfactant and water and/or a water-miscible low-boiling solvent. As an alternative method, the hydrophilic fibroin-coated pigment can be produced by spraying the above mixed solution uniformly to the above pigment and drying the product. The HLB value of the hydrophilic nonionic surfactant is preferably 10-18.
The present disclosure relates to an oligopeptide. The oligopeptide includes an amino acid sequence having at least 50% identity with at least one of full-length amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4. The present disclosure also relates to a testing kit including the oligopeptide and a medical composition including the oligopeptide. Therefore, it has application potentials in related arts.
This is an in vivo study using serial IM testosterone undeconate injections in participants undergoing knee surgery with limited weight bearing post-operatively which includes partial/total knee replacement, ACL reconstruction/revision, meniscal allograft transplantation and articular cartilage paste grafting. The design is a randomized, controlled, double blind, longitudinal study of intra-muscular injections of testosterone versus saline control. Pre-operative and post-operative assessments will include: serial MRIs and manual measurements of quadriceps cross-section and knee pain and function survey, KOOS. Blood analysis will be performed for therapeutic assessment and safety. The participant will receive two testosterone undeconate injections, once during their pre-operative visit and once during their 1 month visit. Timing of assessments will be pre-operative, 1-4 days post-operative and 1, 3, and 6 months. Measurement of the control group versus experimental group at all time points may identify differences in participant response to testosterone injections.